Cambridge NeuroScience Reports Positive Results From Pain Study
Next Step Phase II Study in Patients
CAMBRIDGE, Mass., Jan. 6 /PRNewswire/ -- Cambridge NeuroScience, Inc. (Nasdaq: CNSI - news) today
announced the results of a Phase I clinical trial comparing the effects of CNS 5161 to morphine and placebo in
volunteers exposed to a painful stimulus. CNS 5161, a non-competitive blocker of the N- methyl D-aspartate
(NMDA) ion-channel complex, is the first of a series of small molecules with various biological mechanisms
being developed by Cambridge NeuroScience for the potential treatment of neuropathic pain and migraine.
The clinical study examined the reduction in pain experienced after placebo, morphine and two separate doses of
CNS 5161 (0.25mg and 0.5mg), administered on separate occasions to sixteen male volunteers. CNS 5161 at
0.5mg was found to produce a statistically significant reduction in perceived pain as compared to either
morphine or placebo.
''The results from this study are encouraging and validate our research efforts in this field. This initial success
with CNS 5161 in ameliorating pain bodes well for our pain program which is exploring compounds with
different therapeutic approaches,'' commented Elkan R. Gamzu, Ph.D., President and Chief Executive Officer of
Cambridge NeuroScience. ''The adequacy of this low dose of the drug to relieve pain will facilitate the
exploration of different dosage forms. Plans are now being finalized for further clinical studies in patients with
neuropathic or persistent pain.''
Animal studies have shown that CNS 5161 can prevent the development of a delayed pain response, which is
thought to be related to the development of centrally mediated pain in humans following viral infection, surgery
or trauma. Estimates of the potential market for the prevention of neuropathic pain range from 400,000 to
900,000 patients annually in the United States alone.
Cambridge NeuroScience, Inc. is a leading neuroscience company engaged in the discovery and development of
proprietary pharmaceuticals focusing on nerve cell survival. The Company is developing a number of products to
treat stroke, traumatic brain injury and chronic neurodegenerative disorders such as multiple sclerosis,
peripheral neuropathies and other degenerative diseases.
This press release contains forward-looking statements based on the current expectations of management. There
are certain important factors that could cause results to differ from those anticipated by the statements made
above, including, but not limited to, the results of the scientific research programs described above, the strategic
interests of Cambridge NeuroScience in pursuing the project as well as the results of future clinical trials, and
the acceptance by regulatory authorities of the Company's clinical trial outcomes as a basis for marketing
approval. |
